Page 28 - Advanced Accelerator Applications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced accelerator applications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Accelerator Applications Today - Breaking & Trending Today

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Share this article
Share this article
EAST HANOVER, N.J., June 3, 2021 /PRNewswire/ Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera
® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR to 60 mg of octreotide LAR in patients with midgut neuroendocrine tumors. The previously reported primary analysis of the trial demonstrated a statistically significant improvement in progression free survival (PFS) (HR: 0.18 , p 0.0001)
3. In the final analysis of overall survival, a secondary objective of the trial, treatment with Lutathera resulted in a clinically relevant prolongation in median overall survival of 11.7 months [48.0 months (95%CI: 37.4-55.2) compared to the control arm (36.3 months (95%CI: 25.9-51.7)] ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Rachel Levine , Prnewswire Novartis , Nuclear Medicine Through Innovation , Virtual Scientific Program , Novartis Company , Elsevier Inc , Novartis External Communications , Exchange Commission , National Cancer Institute Surveillance , National Research Council , Institute Of Medicine , Novartis Pharmaceuticals Corporation , National Academies , Scientific Program , National Cancer Institute , End Results , Advanced Accelerator Applications , Accelerator Applications , Positron Emission Tomography , Single Photon Emission Computed Tomography ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Rachel Levine , Nuclear Medicine Through Innovation , Virtual Scientific Program , Novartis Company , Elsevier Inc , Novartis External Communications , Exchange Commission , National Cancer Institute Surveillance , National Research Council , Institute Of Medicine , National Academies , Scientific Program , National Cancer Institute , End Results , Advanced Accelerator Applications , Prescribing Information , Accelerator Applications , Positron Emission Tomography , Single Photon Emission Computed Tomography , Midgut Neuroendocrine ,

Sheldon Gross Realty brokers sale of 5,000-square-foot flex space in Milburn

Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary ....

Advanced Accelerator Applications ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

NOVARTIS AG CHF0.50(REGD)
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Overall survival and radiographic PFS from phase III study of investigational radioligand therapy
177
Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary
New Kisqali (ribociclib) overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer
Phase II results for oral, targeted factor B inhibitor iptacopan (LNP023) as ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Susanne Schaffert , Fiona Phillips , American Society Of Clinical Oncology , Novartis Institutes For Biomedical Research , Astex Pharmaceuticals , European Hematology Association , Novartis Strategy Financial Communications , Novartis Oncology Communications , Novartis Us External Communications , Exchange Commission , Virtual Congress , Incyte Corporation , Clinical Oncology , Annual Meeting , Hematology Association , Disease Control , With Hormone Receptor Positive , Altered Advanced Breast Cancer , Treated With Alpelisib , Adult Patients ,

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Susanne Schaffert , Fiona Phillips , American Society Of Clinical Oncology , Novartis Institutes For Biomedical Research , Astex Pharmaceuticals , European Hematology Association , Novartis Strategy Financial Communications , Novartis Oncology Communications , Novartis Us External Communications , Exchange Commission , Novartis Pharmaceuticals Corporation , Virtual Congress , Incyte Corporation , Clinical Oncology , Annual Meeting , Hematology Association , Disease Control , With Hormone Receptor Positive , Altered Advanced Breast Cancer , Treated With Alpelisib ,